# Determination of Prevalence and Features of HRRm mCRPC (ADAM)

> **NCT04712890** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 331 (actual)

## Conditions studied

- HRRm mCRPC

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04712890
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-23
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 331 (ACTUAL)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04712890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04712890, "Determination of Prevalence and Features of HRRm mCRPC (ADAM)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04712890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*